Immunogenicity and safety of BNT162b2 mRNA vaccine in outpatients on dialysis: Double center prospective observational study in Japan

Immunogenicity and safety of BNT162b2 mRNA vaccine in outpatients on dialysis: Double center prospective observational study in Japan - Immunogenicity and safety of BNT162b2 mRNA vaccine in outpatients on dialysis: Double center prospective observational study in Japan

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000044500

Enrollment

150

Registered

2021-06-11

Start date

2021-06-11

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

dialysis patients

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: patient who have been attending the dialysis center of our hospitals during the above registration period

Exclusion criteria

Exclusion criteria: aged <16 years being infected SARS-CoV-2 and in isolation having already received the vaccine not wishing to be vaccinated by their own choice or on the recommendation of their physician; and did not provide informed consent.

Design outcomes

Primary

Measure	Time frame
Antibody titer of anti-spike protein IgG before first vaccination, at the time of the second vaccination, and 14 days after the second vaccination, 90 days, and 180 days after vaccination	—

Countries

Japan

Contacts

Public ContactMakoto Hibino

Shonan Fujisawa Tokushukai Hospital Respiratory Medicine

chigasaki30@gamil.com0466351177

Outcome results